Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2019 Filed Sep 20, 2019 20:05 UTC Amendment |
Hecht Peter MDirector · Chief Executive Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 223,893 | $0.00 Strike: $11.28 | $0.00 |
DisclosureSEC source: 0001209191-19-050311 · doc4a.xml · derivative · entry 6 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,893 Underlying: Common Stock · 223,893 shares Expires 2026-03-01 F5 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2016. F4 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:05 UTC Amendment |
Hecht Peter MDirector · Chief Executive Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 37,972 | $0.00 Strike: $15.54 | $0.00 |
DisclosureSEC source: 0001209191-19-050311 · doc4a.xml · derivative · entry 5 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,972 Underlying: Common Stock · 37,972 shares Expires 2024-03-03 F3 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. F4 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:05 UTC Amendment |
Hecht Peter MDirector · Chief Executive Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 43,679 | $0.00 Strike: $14.40 | $0.00 |
DisclosureSEC source: 0001209191-19-050311 · doc4a.xml · derivative · entry 4 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,679 Underlying: Common Stock · 43,679 shares Expires 2023-02-01 F3 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. F4 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:05 UTC Amendment |
Hecht Peter MDirector · Chief Executive Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 36,088 | $0.00 Strike: $16.21 | $0.00 |
DisclosureSEC source: 0001209191-19-050311 · doc4a.xml · derivative · entry 3 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,088 Underlying: Common Stock · 36,088 shares Expires 2022-02-01 F3 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. F4 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:05 UTC Amendment |
Hecht Peter MDirector · Chief Executive Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 53,083 | $0.00 Strike: $12.24 | $0.00 |
DisclosureSEC source: 0001209191-19-050311 · doc4a.xml · derivative · entry 2 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,083 Underlying: Common Stock · 53,083 shares Expires 2021-02-01 F2 · derivative.exercise_price: This report has been amended to correct the exercise price of the stock options that were originally issued by Ironwood in connection with the Separation. F3 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. F4 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:05 UTC Amendment |
Hecht Peter MDirector · Chief Executive Officer
|
GrantCommon Stock | 221,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-050311 · doc4a.xml · nonDerivative · entry 1 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,736 F1 · balance_after: This report has been amended to reflect the number of shares received in a pro rata distribution by Ironwood Pharmaceuticals, Inc. ("Ironwood") as a result of the spin-off of the Issuer from Ironwood, effective on April 1, 2019 (the "Separation"). Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:02 UTC Amendment |
Currie Mark GPresident
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 514,698 | $0.00 Strike: $14.21 | $0.00 |
DisclosureSEC source: 0001209191-19-050309 · doc4a.xml · derivative · entry 8 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514,698 Underlying: Common Stock · 514,698 shares Expires 2029-01-29 F1 · derivative.exercise_price: This report has been amended to correct the exercise price of the stock options that were originally issued by Ironwood Pharmaceuticals, Inc. ("Ironwood") as a result of the spin-off of the Issuer from Ironwood, effective on April 1, 2019 ("the Separation"). F8 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2019. F3 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:02 UTC Amendment |
Currie Mark GPresident
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 140,984 | $0.00 Strike: $16.02 | $0.00 |
DisclosureSEC source: 0001209191-19-050309 · doc4a.xml · derivative · entry 7 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,984 Underlying: Common Stock · 140,984 shares Expires 2028-02-21 F7 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2018. F3 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:02 UTC Amendment |
Currie Mark GPresident
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 113,413 | $0.00 Strike: $18.47 | $0.00 |
DisclosureSEC source: 0001209191-19-050309 · doc4a.xml · derivative · entry 6 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,413 Underlying: Common Stock · 113,413 shares Expires 2027-02-27 F1 · derivative.exercise_price: This report has been amended to correct the exercise price of the stock options that were originally issued by Ironwood Pharmaceuticals, Inc. ("Ironwood") as a result of the spin-off of the Issuer from Ironwood, effective on April 1, 2019 ("the Separation"). F6 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2017. F3 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:02 UTC Amendment |
Currie Mark GPresident
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 50,794 | $0.00 Strike: $11.28 | $0.00 |
DisclosureSEC source: 0001209191-19-050309 · doc4a.xml · derivative · entry 5 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,794 Underlying: Common Stock · 50,794 shares Expires 2026-03-01 F5 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 1, 2016. F3 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:02 UTC Amendment |
Currie Mark GPresident
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $17.20 | $0.00 |
DisclosureSEC source: 0001209191-19-050309 · doc4a.xml · derivative · entry 4 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2025-03-01 F4 · derivative.exercise_date: This footnote has been amended to reflect the number of unvested options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. This option to purchase 25,208 shares vests in equal installments upon achievement of certain regulatory and commercial milestones. The option has vested as to 2,500 shares as of the date hereof. F4 · balance_after: This footnote has been amended to reflect the number of unvested options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. This option to purchase 25,208 shares vests in equal installments upon achievement of certain regulatory and commercial milestones. The option has vested as to 2,500 shares as of the date hereof. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:02 UTC Amendment |
Currie Mark GPresident
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 27,772 | $0.00 Strike: $14.40 | $0.00 |
DisclosureSEC source: 0001209191-19-050309 · doc4a.xml · derivative · entry 3 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,772 Underlying: Common Stock · 27,772 shares Expires 2023-02-01 F2 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. F3 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:02 UTC Amendment |
Currie Mark GPresident
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 17,490 | $0.00 Strike: $16.21 | $0.00 |
DisclosureSEC source: 0001209191-19-050309 · doc4a.xml · derivative · entry 2 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,490 Underlying: Common Stock · 17,490 shares Expires 2022-02-01 F2 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. F3 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 20:02 UTC Amendment |
Currie Mark GPresident
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 37,279 | $0.00 Strike: $12.24 | $0.00 |
DisclosureSEC source: 0001209191-19-050309 · doc4a.xml · derivative · entry 1 Currie Mark G · CIK 0001478244 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,279 Underlying: Common Stock · 37,279 shares Expires 2021-02-01 F1 · derivative.exercise_price: This report has been amended to correct the exercise price of the stock options that were originally issued by Ironwood Pharmaceuticals, Inc. ("Ironwood") as a result of the spin-off of the Issuer from Ironwood, effective on April 1, 2019 ("the Separation"). F2 · derivative.exercise_date: This option, granted as an annual performance award, is presently exercisable in full. F3 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 16:01 UTC Amendment |
Huyett WilliamChief Financial Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 221,964 | $0.00 Strike: $14.21 | $0.00 |
DisclosureSEC source: 0001209191-19-050308 · doc4a.xml · derivative · entry 4 Huyett William · CIK 0001723846 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,964 Underlying: Common Stock · 221,964 shares Expires 2029-01-29 F5 · derivative.exercise_price: This report has been amended to correct the exercise price of the stock options that were originally issued by Ironwood in connection with the Separation. F7 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of common stock on each monthly anniversary of January 1, 2019. F2 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 16:01 UTC Amendment |
Huyett WilliamChief Financial Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 221,312 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0001209191-19-050308 · doc4a.xml · derivative · entry 3 Huyett William · CIK 0001723846 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,312 Underlying: Common Stock · 221,312 shares Expires 2028-01-02 F5 · derivative.exercise_price: This report has been amended to correct the exercise price of the stock options that were originally issued by Ironwood in connection with the Separation. F6 · derivative.exercise_date: The option, granted as a new hire award, vested as to 25% of the shares of common stock on December 15, 2018, and 2.08333% of the shares of common stock vest each month thereafter for the next 36 months. F2 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 16:01 UTC Amendment |
Huyett WilliamChief Financial Officer
|
GrantCommon Stock | 39,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-050308 · doc4a.xml · nonDerivative · entry 2 Huyett William · CIK 0001723846 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,898 F3 · shares: In connection with the Separation, the reporting person received a grant of 39,172 restricted stock units, each representing the right to receive a share of Cyclerion common stock, as a result of the adjustment of existing Ironwood restricted stock units held by the reporting person prior to the Separation. The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of common stock on the approximate anniversary of the grant. F4 · balance_after: This report has been amended to reflect the number of shares received in a pro rata distribution as a result of the Separation. Read SEC document |
| April 01, 2019 Filed Sep 20, 2019 16:01 UTC Amendment |
Huyett WilliamChief Financial Officer
|
GrantCommon Stock | 38,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-050308 · doc4a.xml · nonDerivative · entry 1 Huyett William · CIK 0001723846 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,320 F1 · shares: In connection with the separation of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals Inc. ("Ironwood") effective April 1, 2019 (the "Separation"), the reporting person received a grant of 38,320 restricted stock units, each representing the right to receive a share of Cyclerion common stock, as a result of the adjustment of existing Ironwood restricted stock units held by the reporting person prior to the Separation. The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of common stock on the approximate anniversary of the grant. F2 · balance_after: This report has been amended to reflect the number of options that were assumed by the Issuer under its applicable mirror equity plan as a result of the Separation. Read SEC document |
| March 29, 2019 Filed Apr 3, 2019 01:39 UTC |
IRONWOOD PHARMACEUTICALS INC10% owner
|
GrantCommon Stock | 15,562,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-019466 · a4.xml · nonDerivative · entry 1 IRONWOOD PHARMACEUTICALS INC · CIK 0001446847 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,562,555 F1 · kind: On March 29, 2019, Cyclerion Therapeutics, Inc. ("Cyclerion") issued a dividend of 155,624.55 shares of its common stock for each share of its common stock outstanding. As the sole holder of Cyclerion's common stock, Ironwood Pharmaceuticals, Inc. ("Ironwood") received 15,562,455 shares of common stock in the dividend. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.